evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

959 questions · 987 findings · 78 reviews · Haematology

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 256 · 25.9%GRADE not reported 64 · 6.5%Very low 207 · 21%Low 247 · 25%Moderate 163 · 16.5%High 50 · 5.1%

Prophylactic platelet transfusion vs platelet‐poor plasma

Mortality: secondary to bleeding · People with a haematological disorder

It is very uncertain whether prophylactic platelet transfusion changes mortality: secondary to bleeding compared with platelet‐poor plasma (very low certainty).

1 finding from 1 review

Prophylactic platelet transfusion vs non prophylactic or therapeutic platelet transfusion

Bleeding: Number of days on which a significant bleeding event occurred3 · People with a haematological disorder

Prophylactic platelet transfusion showed no clear difference in bleeding: Number of days on which a significant bleeding event… compared with non prophylactic or therapeutic platelet transfusion (low certainty).

1 finding from 1 review

Prophylactic platelet transfusion vs non prophylactic or therapeutic platelet transfusion

Mortality: secondary to bleeding · People with a haematological disorder

Prophylactic platelet transfusion showed no clear difference in mortality: Secondary to bleeding compared with non prophylactic or therapeutic platelet transfusion (low certainty).

1 finding from 1 review

Prophylactic platelet transfusion at threshold of 10,000 vs higher transfusion threshold (20,000 or 30,000)

Bleeding: Numbers of patients with at least one significant bleeding event · People with a haematological disorder

Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in bleeding: Numbers of patients with at least one significant bleeding… compared with higher transfusion threshold (20,000 or 30,000) (moderate certainty).

1 finding from 1 review

Prophylactic platelet transfusion at threshold of 10,000 vs higher transfusion threshold (20,000 or 30,000)

Mortality: secondary to bleeding · People with a haematological disorder

Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in mortality: secondary to bleeding compared with higher transfusion threshold (20,000 or 30,000) (low certainty).

1 finding from 1 review

Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical

Overall survival: Median length of · people with chronic lymphocytic leukaemia

Anti‐leukaemic therapy plus alemtuzumab probably leads to lower overall survival (median 2 years) compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (moderate certainty).

1 finding from 1 review

Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy without alemtuzumab (anti‐leukaemic therapy not identical

Treament related mortality · people with chronic lymphocytic leukaemia

Anti‐leukaemic therapy with alemtuzumab showed no clear difference in treament related mortality compared with anti‐leukaemic therapy without alemtuzumab (anti‐leukaemic therapy… (low certainty).

1 finding from 1 review

Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy without alemtuzumab (anti‐leukaemic therapy not identical

Complete response · people with chronic lymphocytic leukaemia

Anti‐leukaemic therapy with alemtuzumab showed no clear difference in complete response rate compared with anti‐leukaemic therapy without alemtuzumab (anti‐leukaemic therapy… (moderate certainty).

1 finding from 1 review

Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical

Progression‐free survival · people with chronic lymphocytic leukaemia

Anti‐leukaemic therapy plus alemtuzumab may leads to lower progression free survival (median 2 years) compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (low certainty).

1 finding from 1 review

Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical

Treatment related mortality · people with chronic lymphocytic leukaemia

Anti‐leukaemic therapy plus alemtuzumab showed no clear difference in treatment related mortality compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (moderate certainty).

1 finding from 1 review

Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical

Cytomegalovirus reactivation · people with chronic lymphocytic leukaemia

Anti‐leukaemic therapy plus alemtuzumab leads to higher cytomegalovirus reactivation compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (high certainty).

1 finding from 1 review

Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical

Complete response · people with chronic lymphocytic leukaemia

Anti‐leukaemic therapy plus alemtuzumab may leads to higher complete response rate compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (low certainty).

1 finding from 1 review